Clinical trial aimed at evaluating the safety and performance of the ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System for CE mark approval purposes.
Single arm, prospecitve, multicenter, non-randomized and open trial. The purpose of this trial is to collect and safety and performance data concerning the ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System The ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System are intended for use in minimally invasive, transcatheter aortic valve replacement (TAVR) using transfemoral access in patients presenting with severe aortic valve stenosis. The primary objective is to evaluate the safety and performance of the study device in patients presenting with severe aortic stenosis (AS) considered to be high risk for surgery. The secondary objective is to evaluate adverse events and study device performance.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Transcatheter aortic valve replacement via transfemoral access
Rigshospitalet
Copenhagen, Denmark
Kerckhoff-Klinik Forschungsgesellschaft mbH
Bad Nauheim, Germany
Johannes Hospital
Dortmund, Germany
Universitätsklinikum Halle - Universitätsklinik und Poliklinik für Herzchirurgie
Rate of all-cause mortality at 30 days follow-up
Time frame: 30 days post-implant
Rate of clinical events as defined per VARC guidelines
Clinical events: * Mortality * Stroke * Myocardial infarction * Bleeding complication * Acute kidney injury * Vascular complication * Conduction disturbances and arrhythmia * Other TAVI-related complications
Time frame: 7 days, 30 days, 12 months post-implant
Procedural success
2\. Procedural success defined as absence of complications arising during implantation of the prosthetic valve such as: inability to properly seat the valve in the annulus; need for more than one aortic bioprosthesis (valve in valve); or if a surgical aortic valve replacement is required to correct a severe aortic regurgitation or procedure complication
Time frame: Day of implant
Device success
3\. Device success defined as: * Absence of intra-procedure mortality AND, * Correct positioning of a single prosthetic heart valve into the proper anatomical location AND, * Intended performance of the prosthetic heart valve (EOAi \>0.85 cm2/m2 and mean aortic valve gradient \<20mmHg without moderate or severe AR)
Time frame: Day of implant
VARC Composite Safety at 30 days
Time frame: 30 days
Clinical improvement from baseline as per NYHA Functional Classification
Time frame: 7 days, 30 days, 12 months post-implant
Improvement from baseline in hemodynamic function: effective orifice area, mean transprosthetic gradient
Time frame: 7 days, 30 days, 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Halle, Germany
Universitäres Herzzentrum Hamburg - Klinik und Poliklinik für Herz- und Gefäßchirurgie
Hamburg, Germany
Herzzentrum Leipzig GmbH
Leipzig, Germany
Deutsches Herzzentrum München
München, Germany
Universitätsklinik Regensburg
Regensburg, Germany
Luzerner Kantonsspital
Lucerne, Switzerland
Total aortic regurgitation
Time frame: 7 days, 30 days, 12 months